Cargando…
Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results
IMPORTANCE: Magnetic resonance imaging (MRI) and potential MRI-guided biopsy enable enhanced identification of clinically significant prostate cancer. Despite proven efficacy, MRI and potential MRI-guided biopsy remain costly, and there is limited evidence regarding the cost-effectiveness of this ap...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687655/ https://www.ncbi.nlm.nih.gov/pubmed/38019516 http://dx.doi.org/10.1001/jamanetworkopen.2023.44856 |
_version_ | 1785152018083479552 |
---|---|
author | Yun, Hyunkyung Kim, Jin Gandhe, Aishwarya Nelson, Brianna Hu, Jim C. Gulani, Vikas Margolis, Daniel Schackman, Bruce R. Jalali, Ali |
author_facet | Yun, Hyunkyung Kim, Jin Gandhe, Aishwarya Nelson, Brianna Hu, Jim C. Gulani, Vikas Margolis, Daniel Schackman, Bruce R. Jalali, Ali |
author_sort | Yun, Hyunkyung |
collection | PubMed |
description | IMPORTANCE: Magnetic resonance imaging (MRI) and potential MRI-guided biopsy enable enhanced identification of clinically significant prostate cancer. Despite proven efficacy, MRI and potential MRI-guided biopsy remain costly, and there is limited evidence regarding the cost-effectiveness of this approach in general and for different prostate-specific antigen (PSA) strata. OBJECTIVE: To examine the cost-effectiveness of integrating annual MRI and potential MRI-guided biopsy as part of clinical decision-making for men after being screened for prostate cancer compared with standard biopsy. DESIGN, SETTING, AND PARTICIPANTS: Using a decision analytic Markov cohort model, an economic evaluation was conducted projecting outcomes over 10 years for a hypothetical cohort of 65-year-old men in the US with 4 different PSA strata (<2.5 ng/mL, 2.5-4.0 ng/mL, 4.1-10.0 ng/mL, >10 ng/mL) identified by screening through Monte Carlo microsimulation with 10 000 trials. Model inputs for probabilities, costs in 2020 US dollars, and quality-adjusted life-years (QALYs) were from the literature and expert consultation. The model was specifically designed to reflect the US health care system, adopting a federal payer perspective (ie, Medicare). EXPOSURES: Magnetic resonance imaging with potential MRI-guided biopsy and standard biopsy. MAIN OUTCOMES AND MEASURES: Incremental cost-effectiveness ratios (ICERs) using a willingness-to-pay threshold of $100 000 per QALY was estimated. One-way and probabilistic sensitivity analyses were performed. RESULTS: For the 3 PSA strata of 2.5 ng/mL or greater, the MRI and potential MRI-guided biopsy strategy was cost-effective compared with standard biopsy (PSA 2.5-4.0 ng/mL: base-case ICER, $21 131/QALY; PSA 4.1-10.0 ng/mL: base-case ICER, $12 336/QALY; PSA >10.0 ng/mL: base-case ICER, $6000/QALY). Results varied depending on the diagnostic accuracy of MRI and potential MRI-guided biopsy. Results of probabilistic sensitivity analyses showed that the MRI and potential MRI-guided biopsy strategy was cost-effective at the willingness-to-pay threshold of $100 000 per QALY in a range between 76% and 81% of simulations for each of the 3 PSA strata of 2.5 ng/mL or more. CONCLUSIONS AND RELEVANCE: This economic evaluation of a hypothetical cohort suggests that an annual MRI and potential MRI-guided biopsy was a cost-effective option from a US federal payer perspective compared with standard biopsy for newly eligible male Medicare beneficiaries with a serum PSA level of 2.5 ng/mL or more. |
format | Online Article Text |
id | pubmed-10687655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-106876552023-12-01 Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results Yun, Hyunkyung Kim, Jin Gandhe, Aishwarya Nelson, Brianna Hu, Jim C. Gulani, Vikas Margolis, Daniel Schackman, Bruce R. Jalali, Ali JAMA Netw Open Original Investigation IMPORTANCE: Magnetic resonance imaging (MRI) and potential MRI-guided biopsy enable enhanced identification of clinically significant prostate cancer. Despite proven efficacy, MRI and potential MRI-guided biopsy remain costly, and there is limited evidence regarding the cost-effectiveness of this approach in general and for different prostate-specific antigen (PSA) strata. OBJECTIVE: To examine the cost-effectiveness of integrating annual MRI and potential MRI-guided biopsy as part of clinical decision-making for men after being screened for prostate cancer compared with standard biopsy. DESIGN, SETTING, AND PARTICIPANTS: Using a decision analytic Markov cohort model, an economic evaluation was conducted projecting outcomes over 10 years for a hypothetical cohort of 65-year-old men in the US with 4 different PSA strata (<2.5 ng/mL, 2.5-4.0 ng/mL, 4.1-10.0 ng/mL, >10 ng/mL) identified by screening through Monte Carlo microsimulation with 10 000 trials. Model inputs for probabilities, costs in 2020 US dollars, and quality-adjusted life-years (QALYs) were from the literature and expert consultation. The model was specifically designed to reflect the US health care system, adopting a federal payer perspective (ie, Medicare). EXPOSURES: Magnetic resonance imaging with potential MRI-guided biopsy and standard biopsy. MAIN OUTCOMES AND MEASURES: Incremental cost-effectiveness ratios (ICERs) using a willingness-to-pay threshold of $100 000 per QALY was estimated. One-way and probabilistic sensitivity analyses were performed. RESULTS: For the 3 PSA strata of 2.5 ng/mL or greater, the MRI and potential MRI-guided biopsy strategy was cost-effective compared with standard biopsy (PSA 2.5-4.0 ng/mL: base-case ICER, $21 131/QALY; PSA 4.1-10.0 ng/mL: base-case ICER, $12 336/QALY; PSA >10.0 ng/mL: base-case ICER, $6000/QALY). Results varied depending on the diagnostic accuracy of MRI and potential MRI-guided biopsy. Results of probabilistic sensitivity analyses showed that the MRI and potential MRI-guided biopsy strategy was cost-effective at the willingness-to-pay threshold of $100 000 per QALY in a range between 76% and 81% of simulations for each of the 3 PSA strata of 2.5 ng/mL or more. CONCLUSIONS AND RELEVANCE: This economic evaluation of a hypothetical cohort suggests that an annual MRI and potential MRI-guided biopsy was a cost-effective option from a US federal payer perspective compared with standard biopsy for newly eligible male Medicare beneficiaries with a serum PSA level of 2.5 ng/mL or more. American Medical Association 2023-11-29 /pmc/articles/PMC10687655/ /pubmed/38019516 http://dx.doi.org/10.1001/jamanetworkopen.2023.44856 Text en Copyright 2023 Yun H et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Original Investigation Yun, Hyunkyung Kim, Jin Gandhe, Aishwarya Nelson, Brianna Hu, Jim C. Gulani, Vikas Margolis, Daniel Schackman, Bruce R. Jalali, Ali Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results |
title | Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results |
title_full | Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results |
title_fullStr | Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results |
title_full_unstemmed | Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results |
title_short | Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results |
title_sort | cost-effectiveness of annual prostate mri and potential mri-guided biopsy after prostate-specific antigen test results |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687655/ https://www.ncbi.nlm.nih.gov/pubmed/38019516 http://dx.doi.org/10.1001/jamanetworkopen.2023.44856 |
work_keys_str_mv | AT yunhyunkyung costeffectivenessofannualprostatemriandpotentialmriguidedbiopsyafterprostatespecificantigentestresults AT kimjin costeffectivenessofannualprostatemriandpotentialmriguidedbiopsyafterprostatespecificantigentestresults AT gandheaishwarya costeffectivenessofannualprostatemriandpotentialmriguidedbiopsyafterprostatespecificantigentestresults AT nelsonbrianna costeffectivenessofannualprostatemriandpotentialmriguidedbiopsyafterprostatespecificantigentestresults AT hujimc costeffectivenessofannualprostatemriandpotentialmriguidedbiopsyafterprostatespecificantigentestresults AT gulanivikas costeffectivenessofannualprostatemriandpotentialmriguidedbiopsyafterprostatespecificantigentestresults AT margolisdaniel costeffectivenessofannualprostatemriandpotentialmriguidedbiopsyafterprostatespecificantigentestresults AT schackmanbrucer costeffectivenessofannualprostatemriandpotentialmriguidedbiopsyafterprostatespecificantigentestresults AT jalaliali costeffectivenessofannualprostatemriandpotentialmriguidedbiopsyafterprostatespecificantigentestresults |